Point72 Europe London LLP Makes New $1.40 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Point72 Europe London LLP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,335 shares of the biopharmaceutical company's stock, valued at approximately $1,403,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC increased its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new position in Halozyme Therapeutics during the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust raised its position in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now owns 33,108 shares of the company's stock, valued at $2,120,567.40. The trade was a 1.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,697 shares of company stock worth $1,276,552 over the last 90 days. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on HALO shares. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. JPMorgan Chase & Co. lifted their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Price Performance

HALO traded down $0.03 during trading on Wednesday, hitting $53.42. The company's stock had a trading volume of 744,372 shares, compared to its average volume of 1,607,653. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 15.56, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The business's fifty day simple moving average is $60.39 and its 200 day simple moving average is $55.93. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business's revenue was up 35.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.79 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.